REFERENCES
REFERENCES


15. The International Conference on Harmonization (ICH)-Validation of Analytical Procedures: Methodology (Q2B), Food and Drug Administration, USA, Nov. 1996.


21. USP 25–NF 20, Validation of Compendial Methods Section (1225) (United States Pharmacopeia Convention, Rockville, Maryland, USA, 2002) p 2256


27. ISO/IEC 17025, General requirements for the competence of testing and calibration laboratories, 2005.


31. USFDA - Guidance for Industry, Bioanalytical Method Validation


49. Gillies, PS; Dunn, CJ Drugs (August 2000), 60 (2): 333–43; discussion 344–5, "Pioglitazone".


68. *Sauvage, Francois-Ludovic CENG; Stanke-Labesque, Francoise PharmD, PhD; Gagnieu, Marie-Claude PharmD; Jourdil, Jean-Francois CENG; Babany, Gerard MD; Marquet, Pierre MD, PhD*, Volume 31 - Issue 3 - pp 374-381, Therapeutic Drug Monitoring


74. *Siva Kumar Thanikachalam, Manavalan Rajappan and Vallippan Kannappan* Volume 67, Numbers 1-2, 41-47.CHROMATOGRAPHIA, Stability-Indicating HPLC Method for Simultaneous Determination of Pantoprazole and Domperidone from their Combination Drug Product.


84. Chauzit, Emmanuelle PharmD, Bouchet, Stéphane PharmD, Micheau, Marguerite MD, Mahon, François Xavier MD; Moore, Nicholas MD, PhD, Titier, Karine PharmD, Molimard, Mathieu MD, PhD. Therapeutic Drug Monitoring, August 2010 - Volume 32 - Issue 4 - pp 476-481, A Method to Measure Deferasirox in Plasma Using HPLC Coupled With MS/MS Detection and its Potential.


98. Tonks A BMJ 324 (7332): 260. doi:10.1136/bmj.324.7332.260. PMC 1122195. PMID 11823353 (February 2002). "Withdrawal from Paroxetine can be severe, warns FDA".


100. FDA Public Health Advisory Paroxetine”. Food and Drug Administration. Retrieved 05/02/2009.


110. **Rogawski MA, Löscher** Nat Rev Neurosci 5 (7): 553–564, W (Jul 2004), neurobiology The of antiepileptic drugs


113. **Goldberg JF, Calabrese JR, Saville BR, Frye MA, Ketter TA, Suppes T, Post RM, Goodwin FK.** (2009), Clinical Psychiatry 70 (9): 1273–80, "Mood stabilization and destabilization during acute and continuation phase treatment for bipolar I disorder with lamotrigine or placebo".


